

5-14-2013

# Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease

Elena Simon MD

*Fletcher Allen Health Care and the University of Vermont*

Follow this and additional works at: <https://scholarworks.uvm.edu/fammed>



Part of the [Primary Care Commons](#)

---

## Recommended Citation

Simon, Elena MD, "Beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease" (2013). *Family Medicine Scholarly Works*. 2.  
<https://scholarworks.uvm.edu/fammed/2>

This Evidence Review is brought to you for free and open access by the Larner College of Medicine at ScholarWorks @ UVM. It has been accepted for inclusion in Family Medicine Scholarly Works by an authorized administrator of ScholarWorks @ UVM. For more information, please contact [donna.omalley@uvm.edu](mailto:donna.omalley@uvm.edu).

FM Journal Club Bottom Line: Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease

Clinical question: Which patients should be placed/kept on beta-blocker therapy?

Bottom line answer:

- Randomized control trials show beta-blockers benefit patients with systolic congestive heart failure and for the first three years after a patient has a MI.
- Beta-blocker use may not be associated with lower event rates of CV death, non-fatal MI, stroke or hospitalization in patients even with prior history of MI after 3 years.
  - Level 2b evidence: Recent longitudinal study followed 3 cohorts of patients for 44 months with and without beta-blocker use: 1) prior MI 2) CAD no prior MI 3) risk factors for CAD only.
    - There were no significant differences in primary outcomes of cardiovascular death, non-fatal MI or non-fatal stroke in the known MI or CAD without prior MI cohorts
    - In patients with no known CAD history (only risk factors), betablocker use may be associated with increased risk of CV death, non-fatal MI and stroke (HR 1.18, p = 0.02)
    - Secondary outcomes of hospitalization for atheroembolic event and revascularization procedures were increased in patients using beta-blockers who had known CAD but no prior MI and CAD risk factors only.
    - Results were not specified for type or dose of betablocker

Case: 62 year old man who is 5 yrs s/p stent for known MI presents wanting to minimize his medications. Currently taking statin, asa, betablocker, ACEI, metformin. BP 116/72 HgA1c 6.4. Should he stop his betablocker?

Background and supporting evidence:

- AHA 2011 guidelines now recommend betablocker therapy for heart failure patients and MI or ACS patient for 3 years after MI (as class I recommendation)
- AHA guidelines recently changed its recommendation for longterm betablocker therapy from class IIa to class IIb
- European Society of Cardiology now recommends longterm betablocker therapy only for patients with left ventricular systolic dysfunction

Reference: <http://www.ncbi.nlm.nih.gov/pubmed/23032550>

Elena Simon, M.D. Family Medicine Third Year Resident